Drugs / cis-urocanic acid
cis-urocanic acid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01476332 | Nov 2011 → Mar 2012 | dry eye syndrome | Laurantis Pharma, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01458847 | Oct 2009 → Nov 2012 | urinary bladder carcinoma | BioCis Pharma Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cis-urocanic acid | “intravesical cis-urocanic acid (cis-UCA) in patients with primary or recurrent non-muscle invasive bladder cancer” NCT01458847 ↗ |
| Known as | cis-UCA | “intravesical cis-urocanic acid (cis-UCA) in patients with primary or recurrent non-muscle invasive bladder cancer” NCT01458847 ↗ |
| Known as | Imidazole-4-acrylic acid, (z)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1316726 ↗ |
| Known as | NSC-407934 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1316726 ↗ |
| Modality | Small molecule | — CHEMBL1316726 ↗ |
| Route | Other | “intravesical cis-urocanic acid” NCT01458847 ↗ |